Last updated: July 2, 2026
ACADIA Pharmaceuticals v. Aurobindo (1:20-cv-00985): Litigation Summary, Patent Claims, and Generic Entry Risk
ACADIA Pharmaceuticals Inc. sued Aurobindo Pharma Limited in the District of New Jersey over patent infringement tied to Aurobindo’s proposed generic version of an ACADIA product for which ACADIA lists patents in FDA’s Orange Book. The case is docketed as 1:20-cv-00985. The litigation’s core business relevance is whether Aurobindo can launch and at what time, and which specific Orange Book patents (listed for the reference drug) survive the infringement and validity challenges.
What is ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (1:20-cv-00985) about?
Answer: The action is a Hatch-Waxman patent infringement case filed by ACADIA against Aurobindo seeking to block approval and launch of Aurobindo’s proposed generic drug, based on alleged infringement of specific Orange Book–listed patents.
Court, case number, and parties
- Case: ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited
- Docket: 1:20-cv-00985
- Court: United States District Court (District of New Jersey)
Procedural posture and what the case typically turns on
In Hatch-Waxman cases, outcomes are driven by whether the asserted Orange Book patents are:
- Infringed by the proposed generic (often assessed via ANDA product description and generic composition claims).
- Valid (typical defenses include anticipation, obviousness, lack of written description/enablement, indefiniteness).
- Not enforceable (typical defenses include inequitable conduct and prosecution history estoppel, depending on the record).
Which Orange Book patents are asserted in 1:20-cv-00985?
Answer: Not available from the information provided.
A litigation “map” requires the asserted patent numbers (and usually the specific claims). Without the complaint details or docketed infringement contentions, the patent list cannot be produced accurately.
What to expect in the asserted-patent set (typical patterns)
In ACADIA generics disputes, the asserted estate commonly includes one or more of:
- Drug substance patents (composition claims to the active ingredient or salts)
- Drug product patents (formulation, polymorphs, particle size, solid state)
- Method-of-use patents (patient population or dosing regimen)
- Manufacturing/process patents (especially for controlled release or solid-state technologies)
But the specific patent numbers and titles are required to conclude anything for this case.
What did Aurobindo file that triggered the lawsuit (ANDA and Paragraph IV)?
Answer: Not available from the information provided.
Hatch-Waxman lawsuits tied to Orange Book disputes generally correspond to an ANDA filing with a Paragraph IV certification alleging non-infringement and/or invalidity of the asserted patents. However, identifying the exact ANDA and certification requires docket-level or complaint-level specifics.
When does the asserted patent estate expire, and when does exclusivity end?
Answer: Not available from the information provided.
A robust exclusivity and expiration timeline requires at minimum:
- The reference product name
- The Orange Book listing(s) (application numbers, patent numbers, and expiration dates)
- Any non-patent exclusivities (market exclusivity, pediatric exclusivity, 5-year/3-year exclusivity, etc.)
No such listing data is present in the prompt.
How strong is the patent estate for this drug in 1:20-cv-00985?
Answer: Not available from the information provided.
Patent strength analysis depends on:
- Prior litigation history for the same patents
- Claim scope and what Aurobindo’s proposed product is alleged to practice
- The validity record and typical invalidity grounds in similar cases
Without the asserted claims and record, strength cannot be assessed.
What was the outcome of the case: dismissal, settlement, or judgment?
Answer: Not available from the information provided.
To summarize outcome and provide business impact, the record must confirm whether:
- The case was dismissed (with or without prejudice)
- The parties settled (and with what launch/date terms)
- There was a trial or dispositive motions leading to a judgment on infringement/validity
Those facts are not included in the prompt.
If settlement occurred, what terms usually matter
In settlements, the critical business terms are:
- Launch date agreed by the generic
- Workarounds that avoid infringement (labeling changes or product design)
- Payment provisions (where present)
- Stipulated dismissal and covenant not to sue boundaries
No such details are available from the provided input.
What did the court decide on claim construction or dispositive motions?
Answer: Not available from the information provided.
Claim construction rulings can materially narrow or broaden infringement theories. Dispositive motion outcomes (e.g., motion to dismiss, summary judgment) drive timelines for generic approval and are needed for analysis.
Does this litigation affect other generics or create “early mover” pressure?
Answer: Not available from the information provided.
If the asserted patents are central to the Orange Book estate, the case may influence:
- Other ANDA filers waiting on similar patents
- Cross-licensing strategies among challengers
- Risk allocation in generic launch portfolios
But the effect is case-specific and cannot be derived from the prompt.
How does Aurobindo’s generic entry risk compare with other challengers?
Answer: Not available from the information provided.
A cross-company comparison requires:
- The other challengers’ ANDA status
- Their Paragraph IV certifications and which patents they attacked
- Whether courts dismissed or upheld the challenges
- Any settlement-driven launch calendars
No comparator dataset is provided.
What is the FDA status of the ANDA tied to 1:20-cv-00985?
Answer: Not available from the information provided.
FDA status affects practical exclusivity:
- Whether approval was granted or stayed
- Whether a 30-month stay was triggered by the filing date of the infringement suit
- Current approval or tentative approval status
None of these facts are included in the prompt.
Key litigation-driven business questions for ACADIA’s R&D and licensing
Answer: The correct business questions are knowable, but the answers for 1:20-cv-00985 are not determinable from the provided input.
What companies need to know (and why it is case-specific)
- Which patents in the Orange Book are being actively contested
- Whether any survived validity challenges
- Whether a settlement sets a hard launch date or conditional triggers
- Whether Aurobindo is permitted to enter during appeal or after stays lift
Case dossier checklist (what should be extracted from PACER/DOCKET)
Answer: Not available from the information provided.
A complete and accurate litigation dossier requires extracting at least:
- Complaint: asserted patent list and asserted claims
- Answer and defenses: invalidity and non-infringement grounds
- Scheduling orders: Markman deadlines, summary judgment dates, trial dates
- Claim construction opinions
- Dispositive motion rulings
- Settlement/consent judgments and dismissal orders
- Any amended pleadings or infringement contentions
Key Takeaways
- The case ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited, 1:20-cv-00985 is a Hatch-Waxman–style patent infringement dispute tied to a proposed generic entry.
- The litigation’s commercial implications depend on the specific Orange Book patents asserted, the procedural outcome (settlement vs judgment), and any launch-date terms.
- The prompt does not include the asserted patent numbers, the product reference, or docket outcomes, so a concrete litigation summary and risk analysis cannot be generated.
FAQs
- What is a Paragraph IV certification in ACADIA vs Aurobindo generic disputes?
- How does the 30-month stay work in Hatch-Waxman cases like 1:20-cv-00985?
- What documents determine the asserted patents in a pharmaceutical infringement complaint?
- Do settlements in patent cases always include a launch date and payment terms?
- How does claim construction typically change generic infringement outcomes?
References (APA)
- ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited, 1:20-cv-00985 (D.N.J.).
